Back to Search
Start Over
Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia
- Source :
- The Pharmacogenomics Journal. 12:246-254
- Publication Year :
- 2010
- Publisher :
- Springer Science and Business Media LLC, 2010.
-
Abstract
- The goal of this study was to identify genetic markers associated with LY2140023 monohydrate response in patients with schizophrenia. Variants in eight candidate genes related to the mechanism of action of LY2140023 or olanzapine were investigated in a genetic cohort collected from two clinical trials. Results from this genetic analysis indicate that 23 single nucleotide polymorphisms (SNPs) were associated with a change in Positive and Negative Syndrome Scale total score in response to LY2140023 at 28 days (P
- Subjects :
- Adult
Male
Candidate gene
Neuregulin-1
Single-nucleotide polymorphism
Biology
Receptors, Metabotropic Glutamate
Bioinformatics
Polymorphism, Single Nucleotide
Genetic analysis
Russia
Benzodiazepines
Excitatory Amino Acid Agonists
Genetics
medicine
Humans
Receptor, Serotonin, 5-HT2A
Amino Acids
Gene
Genetic association
Pharmacology
Positive and Negative Syndrome Scale
medicine.disease
Introns
United States
Phenotype
Treatment Outcome
Haplotypes
Olanzapine
Pharmacogenetics
Genetic marker
Schizophrenia
Molecular Medicine
Female
Schizophrenic Psychology
Antipsychotic Agents
Subjects
Details
- ISSN :
- 14731150 and 1470269X
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- The Pharmacogenomics Journal
- Accession number :
- edsair.doi.dedup.....fbdf797b62d265ae89a3544c357a9abb
- Full Text :
- https://doi.org/10.1038/tpj.2010.90